China In 2019: Coming Regulatory Changes To Keep On Your Radar
Executive Summary
From heightened overseas manufacturing inspections to a new patent challenge mechanism, important regulatory changes are coming in China this year, and implementation could potentially derail your operations in this key market.
You may also be interested in...
Random Checks Now Routine: China To Inspect Your Factories Near And Far
An officially released new regulation in China legalizes overseas inspections of drug and device makers, making the risk-based inspections routine tasks that could also expand to manufacturers' R&D partners and third-party suppliers of ingredients, excipients or packaging materials.
How One Rogue Scientist Could Sink Global Gene Therapy Progress
Amid a global uproar denouncing a Chinese scientist’s work to deliver gene-edited twin babies, worries emerge that other valuable future research in the area could be put on hold, effectively crippling industry experts and researchers.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.